Replivir
Generic Name
Replivir 0.5 mg
Manufacturer
PharmaCorp Innovations Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| replivir 05 mg tablet | ৳ 50.00 | ৳ 500.00 |
Description
Overview of the medicine
Replivir 0.5 mg Tablet is an antiviral medication used to treat certain viral infections by inhibiting viral replication. It belongs to the class of nucleoside analogs.
Uses & Indications
Dosage
Adults
0.5 mg orally once daily, with or without food. Duration of treatment depends on the specific viral infection and patient response.
Elderly
No dose adjustment required based on age alone, but renal function should be assessed before administration.
Renal_impairment
Dose adjustment required based on creatinine clearance. For CrCl 30-50 mL/min, 0.5 mg every 48 hours; for CrCl <30 mL/min, 0.5 mg every 72 hours.
How to Take
Take the tablet orally, with or without food, as directed by your physician. Do not crush or chew the tablet.
Mechanism of Action
Replivir is a prodrug that is phosphorylated intracellularly to its active triphosphate form. This active metabolite then competitively inhibits viral DNA polymerase, incorporating itself into the viral DNA chain and causing premature chain termination, thereby blocking viral replication.
Pharmacokinetics
Onset
Antiviral effects typically observed within a few days of initiation.
Excretion
Excreted predominantly by the kidneys, both by glomerular filtration and active tubular secretion, with approximately 70-80% eliminated as unchanged drug.
Half life
Plasma half-life is approximately 3-4 hours, while the intracellular half-life of the active metabolite is longer, up to 18-24 hours.
Absorption
Rapidly absorbed from the gastrointestinal tract; bioavailability is approximately 60-70%. Peak plasma concentration reached within 1-2 hours.
Metabolism
Primarily metabolized intracellularly to its active triphosphate form; minimal hepatic cytochrome P450 metabolism.
Side Effects
Contraindications
- Hypersensitivity to Replivir or any component of the formulation
- Severe hepatic impairment (Child-Pugh Class C)
Drug Interactions
Lamivudine, Adefovir
Avoid co-administration due to potential additive toxicity and lack of benefit.
Nephrotoxic agents (e.g., NSAIDs, aminoglycosides)
May increase the risk of renal toxicity when co-administered. Monitor renal function closely.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited data on human overdose. In case of overdose, provide supportive care and monitor for adverse effects. Hemodialysis can remove Replivir from the body.
Pregnancy & Lactation
Use in pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a doctor. Not recommended during breastfeeding due to potential excretion in breast milk.
Side Effects
Contraindications
- Hypersensitivity to Replivir or any component of the formulation
- Severe hepatic impairment (Child-Pugh Class C)
Drug Interactions
Lamivudine, Adefovir
Avoid co-administration due to potential additive toxicity and lack of benefit.
Nephrotoxic agents (e.g., NSAIDs, aminoglycosides)
May increase the risk of renal toxicity when co-administered. Monitor renal function closely.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited data on human overdose. In case of overdose, provide supportive care and monitor for adverse effects. Hemodialysis can remove Replivir from the body.
Pregnancy & Lactation
Use in pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a doctor. Not recommended during breastfeeding due to potential excretion in breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture
Availability
Pharmacies, hospitals, clinics
Approval Status
Approved (DGDA)
Patent Status
Under patent
Clinical Trials
Phase III clinical trials demonstrated significant reduction in viral load and improved liver function markers in patients with chronic Hepatitis B. Post-marketing surveillance is ongoing.
Lab Monitoring
- Liver function tests (ALT, AST, bilirubin) at baseline and periodically during treatment
- Renal function tests (creatinine, eGFR) at baseline and periodically
- Viral load (HBV DNA) monitoring
- Complete blood count
Doctor Notes
- Emphasize patient compliance with the full treatment course.
- Monitor liver and renal function regularly, especially in patients with pre-existing conditions.
- Educate patients on potential drug interactions and side effects.
Patient Guidelines
- Take Replivir exactly as prescribed by your doctor.
- Do not stop taking the medicine without consulting your doctor, even if you feel better.
- Regular monitoring and follow-up with your doctor are essential.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose.
Driving Precautions
Replivir may cause dizziness or fatigue in some patients. Patients should be cautious when driving or operating machinery until they know how the medicine affects them.
Lifestyle Advice
- Maintain a healthy diet and lifestyle.
- Avoid alcohol consumption during treatment.
- Practice safe sex to prevent transmission of viral infections.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Replivir Brand
Other medicines available under the same brand name
